GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro

FAN Editor

Shares of Tesaro soared early Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.

Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula. That represents a premium of more than 60 percent to the stock’s $46.38 closing price Friday. The total deal price includes Tesaro’s net debt.

Continue Reading Below

Glaxo CEO Emma Walmsley said in a statement that the deal will accelerate growth of the British drugmaker’s oncology business.

Zejula brought in $166 million in revenue in the first nine months of this year, with third-quarter sales growing more than 60 percent.

Glaxo expects the deal to close in the first quarter.

Shares of Waltham, Massachusetts-based Tesaro Inc. jumped nearly 60 percent to $73.97 in premarket trading.

Free America Network Articles

Leave a Reply

Next Post

Former President George H.W. Bush to lie in state at U.S. Capitol — live updates

CBS News December 3, 2018, 10:26 AM The casket of former President George H.W. Bush is heading from Texas to Washington, D.C., where the late president will lie in state in the U.S. Capitol from Monday afternoon until Wednesday. The 41st president died late Friday at 94 years old. Flags […]